

# Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/T396FB0485EEN.html>

Date: November 2018

Pages: 111

Price: US\$ 3,500.00 (Single User License)

ID: T396FB0485EEN

## Abstracts

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H2 2018

### SUMMARY

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It is involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. It plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins.

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) pipeline Target constitutes close to 26 molecules. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 6, 1, 10 and 5 respectively. Report covers products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders and Ophthalmology which include indications Rheumatoid Arthritis, Alopecia, Atopic Dermatitis (Atopic Eczema), Psoriasis, Vitiligo, Crohn's Disease (Regional Enteritis), Diffuse Large B-Cell Lymphoma, Inflammation, Ulcerative Colitis, Allergic Conjunctivitis, Androgenic Alopecia, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, Autoimmune Disorders, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-

Hodgkin Lymphoma, Cachexia, Chronic Cutaneous Lupus Erythematosus (CCLE)/Discoid Lupus Erythematosus (DLE), Cutaneous T-Cell Lymphoma, Dermatomyositis, Dermatitis, Follicular Lymphoma, Heart Transplant Rejection, Inflammatory Bowel Disease, Juvenile Rheumatoid Arthritis, Leukemias, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Myeloproliferative Disorders, Peripheral T-Cell Lymphomas (PTCL), Pruritus, Psoriatic Arthritis, Sarcopenia, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma) and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

The latest report Tyrosine Protein Kinase JAK3 - Pipeline Review, H2 2018, outlays comprehensive information on the Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Overview

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Companies Involved in Therapeutics Development

Aclaris Therapeutics Inc

Arrien Pharmaceuticals LLC

Bristol-Myers Squibb Co

Chipscreen Biosciences Ltd

Clevixel Pharma SAS

Daewoong Pharmaceutical Co Ltd

Guangdong Zhongsheng Pharmaceutical Co Ltd

Japan Tobacco Inc

KBP BioSciences Co Ltd

LSK BioPartners Inc

Merck & Co Inc

MYOS RENS Technology Inc

Portola Pharmaceuticals Inc

Sienna Biopharmaceuticals Inc

Sincere Pharmaceutical Group

Theravance Biopharma Inc

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Drug Profiles

ARN-4079 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-1777 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-502 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cerdulatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CS-510 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVXL-0074 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

delgocitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWJ-212 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-7536 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LSK-9985 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OST-122 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OST-246 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peficitinib hydrobromide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06651600 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ITK and JAK3 for Psoriasis and Inflammatory Dermatoses -  
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAK3 for Heart Transplantation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK1 and JAK3 for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK2 and JAK3 for Immunology and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK3 for Cachexia, Rheumatoid Arthritis and Sarcopenia -  
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNA-125 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-1473 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tofacitinib citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tofacitinib citrate ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or  
EC 2.7.10.2) - Dormant Products

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or  
EC 2.7.10.2) - Discontinued Products

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or  
EC 2.7.10.2) - Product Development Milestones

Featured News & Press Releases

Nov 01, 2018: Portola Pharmaceuticals to present new interim phase 2 results for  
Cerdulatinib during an oral session at the 60th American Society of Hematology (ASH)  
Annual Meeting

Oct 22, 2018: Theravance Biopharma reports data from TD-1473 phase 1b four-week  
study in oral late-breaker presentation at UEG Week 2018

Oct 10, 2018: Theravance Biopharma Announces Data from Phase 1b Study of



TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018

Oct 09, 2018: Health Canada approves new indications for Xeljanz in ulcerative colitis (UC) and psoriatic arthritis (PsA)

Sep 25, 2018: Portola Pharmaceuticals receives FDA Orphan Drug Designation for Cerdulatinib, an oral Syk/JAK inhibitor for the treatment of Peripheral T-Cell Lymphoma

Sep 17, 2018: Pfizer reports positive data from Phase IIa study for alopecia areata

Sep 05, 2018: Pfizer receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 inhibitor, for the treatment of patients with Alopecia Areata

Aug 27, 2018: Sienna Biopharmaceuticals announces results from first-in-human study of SNA-125 in psoriasis and continued progression to phase

Aug 01, 2018: Pfizer's Xeljanz secures marketing authorisation in Europe

Jul 09, 2018: FDA grants Fast Track Designation to Aclaris Therapeutics' Investigational JAK Inhibitor for the treatment of Alopecia Areata

Jun 28, 2018: XELJANZ (tofacitinib citrate) Receives Marketing Authorization in the European Union for Active Psoriatic Arthritis

Jun 28, 2018: Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in Patients with Alopecia Areata

Jun 26, 2018: Aclaris Therapeutics Announces First Patient Dosed in a Phase 2 Clinical Trial of ATI-501 Oral Suspension in Patients with Alopecia Totalis and Alopecia Universalis

Jun 04, 2018: New Interim Phase 2a Study Results Demonstrate Broad Clinical Activity of Portola Pharmaceuticals' Oral SYK/JAK Inhibitor Cerdulatinib

Jun 01, 2018: Pfizer Receives Positive CHMP Opinion in European Union for XELJANZ (tofacitinib citrate) for the Treatment of Moderately to Severely Active Ulcerative Colitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018  
Number of Products under Development by Therapy Areas, H2 2018  
Number of Products under Development by Indications, H2 2018  
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018  
Number of Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018 (Contd.1), H2 2018  
Products under Development by Companies, H2 2018 (Contd.2), H2 2018  
Products under Development by Companies, H2 2018 (Contd.3), H2 2018  
Products under Development by Companies, H2 2018 (Contd.4), H2 2018  
Number of Products by Stage and Mechanism of Actions, H2 2018  
Number of Products by Stage and Route of Administration, H2 2018  
Number of Products by Stage and Molecule Type, H2 2018  
Pipeline by Aclaris Therapeutics Inc, H2 2018  
Pipeline by Arrien Pharmaceuticals LLC, H2 2018  
Pipeline by Bristol-Myers Squibb Co, H2 2018  
Pipeline by Chipscreen Biosciences Ltd, H2 2018  
Pipeline by Clevexel Pharma SAS, H2 2018  
Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018  
Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H2 2018  
Pipeline by Japan Tobacco Inc, H2 2018  
Pipeline by KBP BioSciences Co Ltd, H2 2018  
Pipeline by LSK BioPartners Inc, H2 2018  
Pipeline by Merck & Co Inc, H2 2018  
Pipeline by MYOS RENS Technology Inc, H2 2018  
Pipeline by Portola Pharmaceuticals Inc, H2 2018  
Pipeline by Sienna Biopharmaceuticals Inc, H2 2018  
Pipeline by Simcere Pharmaceutical Group, H2 2018  
Pipeline by Theravance Biopharma Inc, H2 2018  
Dormant Products, H2 2018  
Dormant Products, H2 2018 (Contd.1), H2 2018  
Dormant Products, H2 2018 (Contd.2), H2 2018  
Discontinued Products, H2 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

### COMPANIES MENTIONED

Aclaris Therapeutics Inc

Arrien Pharmaceuticals LLC

Bristol-Myers Squibb Co

Chipscreen Biosciences Ltd

Clevexel Pharma SAS

Daewoong Pharmaceutical Co Ltd

Guangdong Zhongsheng Pharmaceutical Co Ltd

Japan Tobacco Inc

KBP BioSciences Co Ltd

LSK BioPartners Inc

Merck & Co Inc

MYOS RENS Technology Inc

Portola Pharmaceuticals Inc

Sienna Biopharmaceuticals Inc

Sincere Pharmaceutical Group

Theravance Biopharma Inc

## I would like to order

Product name: Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/T396FB0485EEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T396FB0485EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

